Drug intelligence / Profile preview

EVX-02B

Development stage: Discontinued
Lead developer: Evaxion Biotech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

EVX-02B is an investigational adjuvant immunotherapy vaccine being evaluated in a Phase 1/2 clinical trial for patients with resected Stage IIIB/IIIC/IIID or Stage IV melanoma who are at high risk of recurrence. It is administered in combination with the anti-PD-1 therapy, Nivolumab. The study aims to assess the safety, tolerability, pharmacodynamics, and efficacy of EVX-02B, delivered via a specific delivery device, as part of a combination immunotherapy regimen.

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on EVX-02B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVX-02B.

Explore the full profile